<P>Mutations of the epidermal growth factor receptor (<I>EGFR</I>) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a firs...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107661986
2013
-
학술저널
100-106(7쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
<P>Mutations of the epidermal growth factor receptor (<I>EGFR</I>) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a firs...
<P>Mutations of the epidermal growth factor receptor (<I>EGFR</I>) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated <I>EGFR</I>. Rapid and accurate <I>EGFR</I> mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for <I>EGFR</I> mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for <I>EGFR</I> mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.</P>
No Detection of Simian Virus 40 in Malignant Mesothelioma in Korea
Mucinous Non-neoplastic Cyst of the Pancreas